Mezzion’s New Drug Application («NDA») for its Orphan Drug Udenafil for the Treatment of Single Ventricle Heart Disease («SVHD») has been Accepted for Filing by the FDA

SEOUL, South Korea, May 25, 2021 /PRNewswire/ — Mezzion Pharma Co., Ltd. (140410.KQ) is pleased to announce today that it has received…

SEOUL, South Korea, May 25, 2021 /PRNewswire/ — Mezzion Pharma Co., Ltd. (140410.KQ) is pleased to announce today that it has received notice from the FDA that its NDA submitted on March 26, 2021 for the use of udenafil to treat SVHD patients who have undergone Fontan palliation is sufficiently complete to permit a substantive review (the «FDA Notice»).

In the FDA Notice, the FDA advised that there were no filing review issues identified.  Thus, the FDA review cycle has started with an expected NDA approval date of March 26, 2022. The FDA also advised in the FDA Notice that the FDA is not currently planning to hold an advisory committee meeting to discuss Mezzion’s NDA.

The FDA had previously granted Mezzion’s request to designate udenafil for treatment of single ventricle congenital heart disease as a drug for a Rare Pediatric Disease.

To encourage the development of drugs to treat rare pediatric diseases, the US established a priority review voucher (PRV) program under which the FDA awards a PRV to a drug sponsor (manufacturer) upon approval of that sponsor’s drug for the treatment of a rare pediatric disease.

Mezzion fully expects that, upon FDA approval of its NDA for the treatment of SVHD patients, a rare pediatric disease, it will be awarded a PRV, at which time the PRV will be fully redeemable and/or transferrable.

Mezzion looks forward to the FDA review process and to bringing a novel pharmacotherapeutic option to this rare pediatric disease population.  

About the Fontan Procedure and Subsequent Expectations

The Fontan procedure is a surgical intervention that allows for the survival of children born with congenital heart disease characterized by only a single functional pumping chamber. This procedure consists of re-configuring the circulation to allow the single ventricle to pump blood to the body while connecting the great veins directly to the arteries that bring blood to the lungs. In this «Fontan circulation» the blood returning from the body bypasses the heart and travels to the lungs without the assistance of a dedicated right ventricle pumping chamber. The goal of the Fontan procedure is to separate the systemic and pulmonary circulations and to improve oxygen levels by redirecting venous blood directly to the lungs.

While the Fontan procedure creates a stable circulation, the risk of hospitalization and cardiac death rises significantly in the second and third decades after Fontan completion, a risk that is associated with a decline in exercise capacity. The Fontan circulation is also associated with non-cardiac complications such as protein-losing enteropathy, plastic bronchitis, and liver failure, all of which can be attributed to a chronic elevation in central venous pressure and a chronically reduced cardiac output. For all of these reasons, a 35 year-old patient who has gone through Fontan palliation has the approximate life expectancy of a 75 year old with normal cardiac physiology.

Mezzion Pharma Co., Ltd.

Mezzion Pharma Co., Ltd. is headquartered in Korea.  Mezzion and its wholly owned subsidiary, Mezzion Pharmaceuticals, Inc., have administrative offices in Deerfield, Illinois and Boca Raton, Florida.  Mezzion Pharma is an innovation-driven pharmaceutical company that is focused on discovering, developing, and commercializing novel therapeutics in the field of rare pediatric diseases.  Mezzion Pharma is a publicly-listed pharmaceutical company in Korea on the Korean stock exchange under (140410:KOSDAQ).

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are «forward-looking statements» within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Mezzion Pharma’s expectations regarding the potential benefits of udenafil; Mezzion Pharma’s expectations regarding the anticipated timing of any future clinical trials; Mezzion Pharma’s expectations on regulatory submissions for marketing approval of udenafil for the treatment of patients that have undergone the Fontan operation, to improve exercise capacity in the United States, including the timing of these submissions; and Mezzion Pharma’s expectations regarding the potential commercial launch of udenafil, including the timing of a potential approval of udenafil. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Mezzion Pharma will need additional funds to finance its operations; Mezzion Pharma’s or any of its collaborative partners’ ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Mezzion Pharma’s or any of its clinical trials will not be successful; Mezzion Pharma’s dependence on the success of udenafil; Mezzion Pharma’s reliance on third parties for the manufacture of Mezzion Pharma’s udenafil and udenafil tablets; possible regulatory developments in the United States and foreign countries; and Mezzion Pharma’s ability to attract and retain senior management personnel.

These and other risks and uncertainties are described more fully in Mezzion Pharma’s most recent filings with the Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of Mezzion Pharma. All forward-looking statements contained in this press release speak only as of the date on which they were made. Mezzion undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:

Dr. James Yeager, Deerfield, Illinois, USA, Tel: +1-847-2122679

Email: james.yeager@mezzion.com 

Mr. S.I. Noh, Seoul, Korea, Tel: +82 2 560 8000

Email: 09428lgtokyo@mezzion.co.kr  

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mezzions-new-drug-application-nda-for-its-orphan-drug-udenafil-for-the-treatment-of-single-ventricle-heart-disease-svhd-has-been-accepted-for-filing-by-the-fda-301299410.html

SOURCE Mezzion Pharma Co. Ltd.